AltPep Corporation Presents New Preclinical Data at AAIC 2025 Demonstrating SOBIN-AD, its Custom-Designed Peptide for Alzheimer's Disease, Increases Clearance of Aβ Toxic Oligomers and Inhibits Plaque Formation
SEATTLE, July 28, 2025--(BUSINESS WIRE)--AltPep Corporation, a privately held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases will today present new preclinical data at the Alzheimer's Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada, reinforcing the promising potential of its lead compound, SOBIN-AD (Soluble Oligomer Binding INhibitor), as a treatment for early Alzheimer's disease (AD).
"We are thrilled to showcase these exciting preclinical results for our SOBIN-AD therapeutic," said Valerie Daggett, Ph.D., CEO and Founder of AltPep. "Our compound is based on the discovery that toxic oligomers, early triggers for amyloid diseases such as AD, form a nonstandard protein structure called α-sheet. We have now demonstrated that SOBIN-AD not only selectively targets the α-sheet toxic oligomers but also enhances clearance of these toxic oligomers."
Carolyn Tallon, Ph.D., Principal Scientist, who will present the AltPep data at AAIC, further commented, "Importantly, we showed that SOBIN-AD treatment improved short-term memory and reduced plaque burden in Tg AD mice, after 6 and 12 months of dosing, respectively. These exciting data mark a major milestone for SOBIN-AD and bring hope for early treatment of AD."
Poster Presentation Details:
Title: Designed peptide increases clearance of Aβ toxic oligomers and inhibits plaque formationPoster #: 104011Date / Time: Monday, July 28, 2025: 7:30 AM – 4:15 PM EDTLocation: Exhibit Hall DE
The poster will also be available in the "Scientific Publications" section of the AltPep website under "Presentations" at https://altpep.com/press/scientific-publications/.
Select preclinical data show SOBIN-AD:
binds Aβ oligomers 27,000-fold stronger than protofibrils;
enhances microglial phagocytosis of toxic Aβ oligomers in a dose-dependent manner;
significantly improves short-term memory in 9-month old Tg2576 AD mice after 6 months of dosing, 3X/week intranasally; and
significantly reduces AB plaque burden in 15-month-old AD mice after 12 months of dosing, 3X/week intranasally.
Gil Block, M.D, Ph.D., and Chief Medical Officer of AltPep remarked, "These results compellingly support the promise of SOBIN-AD as a transformative early treatment option for patients with AD. This achievement is especially important as we advance our program towards the clinic."
About AltPep CorporationAltPep is developing groundbreaking disease-modifying treatments and detection tools for amyloid diseases by targeting early molecular triggers: toxic soluble oligomers. Our customized, synthetic peptides are designed to bind selectively to toxic oligomers to both detect and neutralize them throughout disease progression. AltPep's emphasis is on early, pre-symptomatic detection and treatment. Our lead programs focus on Alzheimer's and Parkinson's diseases, with other amyloid diseases, such as Type 2 diabetes, on the horizon. AltPep's goal is to change the course of these debilitating diseases that affect over a billion people around the globe.
Decades of scientific research by the Daggett Research Group at the UW provided the foundation for AltPep's innovative approach.
About SOBIN Therapeutics and SOBA DiagnosticsSOBIN therapeutics are in development for use in concert with early detection tools to target and neutralize the toxic soluble oligomers associated with amyloid diseases. SOBA diagnostics are highly sensitive, simple blood tests in development to aid in the diagnosis of amyloid diseases.
For more information, please visit altpep.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250728440757/en/
Contacts
Media Contact: Susan SharpeLinnden Communicationssusan@linndencom.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
I'm struggling with thinning hair, so I asked an expert how to avoid hair loss in women. Here's her advice on the best treatments, plus 13 hair product recommendations
If your hair is thinning or you're dealing with hair loss, a dermatologist opens up about products that can make a positive impact. I never thought I would be Googling "why is my hair thinning?" in my late 20s. But a few months ago, I found myself scrolling through endless hair care TikToks and reading articles trying to figure out potential causes — and solutions. While it's normal to shed some hair daily, consistent hair thinning can be the result of underlying issues. And whatever the root cause, hair thinning can affect your mood, confidence and self-esteem. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. For me, it was when I noticed I was parting my hair differently to cover up hair loss that led me to start digging deeper. I tested several products and chatted with Toronto-based dermatologist Dr. Renée Beach to get an expert's perspective. If you're also experiencing thinning hair, below, I break down causes, treatments and products that can make a difference. Jump to: What causes hair loss and thinning in women? Common types of hair thinning What are the most effective treatments for hair thinning? 13 best hair thinning solutions to shop in 2025 Best hair thinning solutions to shop in 2025: Leave-in treatments, shampoos and conditioners What causes hair loss and thinning in women? The truth is, there isn't one clear cut cause of hair thinning — but there are some common causes. "The top causes are androgenetic alopecia — female pattern hair loss — and telogen effluvium, a type of hair shedding where people see the white bulbs of the hair," says Beach. "It's estimated that androgenetic alopecia will affect about 40 to 50 per cent of women by their 40s, and that, at some point in their life, telogen effluvium will affect 70 per cent of women," she explains. Beach says telogen effluvium "can occur at a variety of ages" and can be triggered by a variety of events such as childbirth, bereavement, blood loss or low iron. It's easy to think hair thinning will start later in life, but it may just creep up earlier than expected, she continues. Common types of hair thinning: The location of thinning can say a lot about the underlying causes. These are the most common areas where you might initially notice thinning: Crown: This is the top of the head where one's scalp is more prominent. This is classic for androgenetic alopecia. Temples: You may spot recession here with both androgenetic alopecia and telogen effluvium. When it happens due to telogen effluvium, fine baby hairs will grow back. When it happens in androgenetic alopecia, the vertex (area behind the crown) will also eventually start to thin. Hairline: This can thin out with traction alopecia. What are the most effective treatments for hair thinning? There isn't a one-size-fits-all solution, but there are proven, science-backed treatments that can deliver results. One of the most well-studied and dermatologist-recommended treatments is minoxidil — which some may know as Rogaine or other similar brand names. "5% minoxidil in lotion or foam format has good evidence provided it is applied twice daily and used for 6 months," says Beach. But, once you start, it requires daily and on-going use — unless you're pregnant or breastfeeding. "This is the part that people find difficult to grasp — but just as how you would trim your nails weekly or go to the dentist semi-annually to maintain your teeth, retaining the hair means ongoing use of Rogaine [minoxidil] on some regular schedule," emphasizes Beach. "It's debatable what this schedule may be." How to treat thinning hair: Key ingredients One misconception is that you need to actually treat the hair. Beach says that's not exactly the case. "Hair itself is dead; it's the scalp that is alive," she explains. In order to have healthy hair, it all starts at the scalp. The right ingredients can make all the difference when it comes to supporting hair growth. Specific ingredients in hair treatments, shampoos and conditioners that you may want to look for include biotin for strengthening hair, caffeine to stimulate the scalp or saw palmetto to block hair thinning enzymes. But that said, "none of these would replace minoxidil 5 per cent," says Beach. If you're not ready to go with minoxidil yet, Beach suggests incorporating leave-in products with other key ingredients. "Oftentimes, leave-on products will be more effective than something that is washed in and washed out," she says. Ingredients proven to help with hair growth and thickening: Pumpkin seed Rosemary oil Caffeine Saw palmetto Various amino acids like arginine For me personally, I worked with my doctor to determine my thinning was due to vitamin deficiencies. So I skipped minoxidil, and have been using the Nioxin Hair Fall Defense Serum every night, as well as the Fable and Mane HoliRoots Hair Oil two to three times a week before washing my hair — and I have seen some great progress so far. After six weeks, I started noticing a difference. Less hair was falling out and I've noticed fuller, more voluminous strands. While it can take several months to fully restore hair density from thinning, early results are very encouraging. By addressing my low vitamin levels and using targeted hair thinning products, I've already seen an improvement, but of course, as mentioned, it's not a one-size-fits-all approach. Always speak to your dermatologist or doctor to determine the cause of hair thinning and come up with a plan to improve your scalp and hair from there. 13 best hair thinning solutions to shop in 2025 If you're looking to target thinning hair, check out these treatments, including ones I have tested myself and seen progress with. Best leave-in treatments for thinning hair Best shampoos for thinning hair Best conditioners for thinning hair
Yahoo
an hour ago
- Yahoo
Next Era of Alzheimer's Care Will be Defined by Precision Prevention
New U.S. study reflects growing role of lifestyle interventions, further highlighting need to study lifestyle and drugs in combination NEW YORK, July 28, 2025 /PRNewswire/ -- Results from the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) released today strengthen the case for precision prevention, a strategy set to revolutionize Alzheimer's care by combining lifestyle changes with targeted therapeutics based on individual risk factors. "The future lies in precision prevention," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the Alzheimer's Drug Discovery Foundation. "We have seen this model succeed in cancer and heart disease, and with a growing body of evidence showing neither lifestyle nor drugs can stop Alzheimer's alone, now is the time to double down on studying the two in combination, which will lay the path for precision medicine." The ADDF is driving a new era of clinical trials that look at lifestyle and therapeutic interventions in tandem, including Dr. Miia Kivipelto's MET-FINGER study, which has created a blueprint for combination therapy studies going forward. The U.S. POINTER study, released during the Alzheimer's Association International Conference (AAIC) and published simultaneously in the Journal of the American Medical Association (JAMA), found multidomain lifestyle interventions supported cognitive health in aging populations. This builds on previous findings from Dr. Miia Kivipelto's original FINGER trial, the first to show the critical role of lifestyle changes in preventing dementia. U.S. POINTER showed its structured high-intensity lifestyle interventions benefitted participants regardless of their APOE4 carrier status, a genetic risk factor for Alzheimer's disease. This contrasts findings from the FINGER study, which showed benefit especially in carriers of APOE4, and further highlights the wide-reaching impacts of lifestyle changes. "The U.S. POINTER results validate the findings of the FINGER study in a more diverse U.S. population," said Dr. Kivipelto. "This is yet another proof point that lifestyle can have a tremendous impact on the brain. By developing personalized scientific approaches to match each patient's unique biomarker profile with a combined drug and prevention plan, we are redefining how we treat and prevent Alzheimer's." About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: View original content to download multimedia: SOURCE Alzheimer's Drug Discovery Foundation Inicia sesión para acceder a tu cartera de valores
Yahoo
2 hours ago
- Yahoo
Alzheimer's progression could be slowed by these changes to lifestyle
New research has highlighted how lifestyle can potentially delay the onset of Alzheimer's disease. The most common form of dementia, Alzheimer's impacts nearly 7 million Americans - and that number is projected to nearly double in the next 25 years. The neurodegenerative disease results in memory loss and the decline of other cognitive abilities. On Monday, two studies being presented at the Alzheimer's Association annual meeting have underlined the benefits of diet and exercise. One study shows that walking in particular helps to keep minds sharp by producing a protein called brain-derived neurotrophic factor, or BDNF. 'BDNF is like fertilizer for your brain that is naturally produced, especially when you are being physically active, such as when you are walking,' Cindy Barha, an assistant professor of neuroscience at the University of Calgary, told NBC News. 'It helps brain cells survive, grow and form stronger connections; this supports memory, learning and mood, especially in the hippocampus, which is the brain's memory center.' Walking has frequently been linked to lowering dementia risk, and those who walk more slowly could be showing early signs of the condition. One study involved 3,000 adults and found that those with a gene variant called APOE4 showed steeper declines in their cognitive abilities. Everyone is born with the APOE gene, which plays a critical role in metabolism and brain function. A genetic test can reveal which variant you have, including one that reduces the risk of Alzheimer's and one that doesn't seem to affect the risk. APOE4, which is present in as many as 15 percent of people, increases the risk of Alzheimer's disease. Walking appeared to have the strongest protective effect on individuals with this gene mutation. The second study also found that people with the APOE4 variant could benefit more from lifestyle modifications. The 2,500-person study, which included more than 700 APOE4 carriers, had people exercise, undergo dietary counseling, and complete brain tests. Jenni Lehtisalo, from the Finnish Institute for Health and Welfare, told NBC News that there was about a four times greater benefit for those positive for APOE4. It's unclear exactly why these interventions are so effective for people with APOE4 or when they might be most effective, but the findings build on previous research showing promise in using exercise as a treatment for carriers, and to reduce dementia risk. Other studies have promoted a keto-based diet and additional nutritional approaches to benefit the brain health of these patients. On the other hand, consuming refined sugars and living a more sedentary lifestyle could hurt people with the gene, University of Southern California Alzheimer's researcher Hussein Yassine told Science. 'Modern day life does not work for certain individuals with APOE4,' he said.
